Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program with Encouraging Preliminary Safety Data.

Marker Therapeutics has initiated a Phase 1 RAPID study to investigate its Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product. The first patient treated in the study showed the OTS product was well-tolerated, with safety data consistent with other MAR-T cell studies. Marker aims to remove the bottleneck of individualized cell therapy manufacturing and provide a fast treatment option for patients with aggressive diseases. The company has secured non-dilutive funding to support the clinical investigation of the OTS product.